Cytori Therapeutics, Inc. is a biotechnology company
developing autologous cell therapies from adipose connective tissue designed to
treat a variety of medical conditions. Since 2001, the company has leveraged
its exploration of the massive treatment potential of adult adipose-derived
stem and regenerative cells to position itself as a global leader in the
emerging field of regenerative medicine. By utilizing a patient’s own adipose
tissue, Cytori eliminates the necessity for offsite cell growth operations while
effectively minimizing common transplant risks, including autoimmune rejection.
The company’s current cell therapy pipeline includes three
drug candidates in six unique indications across two countries and the European
Union. Cytori’s leading candidate, ECCS-50, is currently approved in the United
States and Europe to begin a phase III clinical trial for the treatment of
scleroderma hand dysfunction.
According to the National Institute of Health, scleroderma
is a group of diseases that affect connective tissue in the body, potentially
causing swelling or pain in the muscles and joints. Despite affecting as many
as 100,000 people in the United States, there is currently no drug that has
been clearly proven to stop, or reverse, the disease’s key symptoms. For
Cytori, this unmet need should clear the way for favorable results upon the
eventual commercialization of ECCS-50.
From a financial standpoint, Cytori took major steps in the
first quarter of 2015 toward continued development and testing of its promising
product pipeline. The company’s operating cash burn was reduced by over 44
percent in the period and overall contract revenue rose by 350 percent, as
compared to the first quarter of 2014, providing prospective investors with a
preview of the Cytori’s growth potential moving forward.
“We accomplished the key objectives we hoped to achieve over
the past four quarters and are off to a good start in 2015,” Dr. Marc H.
Hendrick, president and chief executive officer of Cytori, stated in a news
release. “Now the lion’s share of our corporate focus and energy will go into
trial enrollment and strategically managing our clinical pipeline.”
In June, the company made progress toward this objective
through the completion of enrollment for its impending phase IIb clinical
trial, which will study the safety, feasibility and dosing intraarticular
administration of Cytori’s ECCO-50 cellular therapeutic in patients with knee
osteoarthritis. Look for the company to build on this progress in the months to
come as it prepares for its pivotal phase III trial of ECCS-50.
For more information, visit www.cytori.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
